213
Participants
Start Date
October 10, 2014
Primary Completion Date
October 2, 2018
Study Completion Date
October 2, 2018
MEDI4893
Participants will receive a single IV dose of MEDI4893 2000 or 5000 mg on Day 1 of the study.
Placebo
Participants will receive a single IV dose of placebo matched to MEDI4893 on Day 1 of the study.
Research Site, Geneva
Research Site, Vác
Research Site, Yvoir
Research Site, Lodelinsart
Research Site, Arlon
Research Site, La Louvière
Research Site, Berlin
Research Site, Berlin
Research Site, Athens
Research Site, Madrid
Research Site, Getafe
Research Site, Atlanta
Research Site, Oviedo
Research Site, Rennes
Research Site, Tours
Research Site, Grenoble
Research Site, Larissa
Research Site, Larissa
Research Site, Nantes
Research Site, Orléans
Research Site, Valencia
Research Site, Valencia
Research Site, Detroit
Research Site, Angers
Research Site, Lille
Research Site, Clermont-Ferrand
Research Site, Alexandroupoli
Research Site, Heidelberg
Research Site, Lyon
Research Site, Pierre-Bénite
Research Site, Le Chesnay
Research Site, Poitiers
Research Site, Limoges
Research Site, Garches
Research Site, Erfurt
Research Site, Brussels
Research Site, Brno
Research Site, Děčín
Research Site, Kyjov
Research Site, Prague
Research Site, Teplice
Research Site, Jena
Research Site, Ioannina
Research Site, Kistarcsa
Research Site, Ponte de Lima
Research Site, Barcelona
Research Site, Barcelona
Research Site, Terrassa
Research Site, Lausanne
Lead Sponsor
Innovative Medicines Initiative
OTHER
Antibacterial Resistance Leadership Group
OTHER
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
MedImmune LLC
INDUSTRY